West Pharmaceutical Services (WST) Notes Payables (2018 - 2024)

West Pharmaceutical Services (WST) has reported Notes Payables for 7 consecutive years, with $132.9 million the latest figure, recorded in Q2 2024.

• Quarterly Notes Payables rose 5940.91% year-over-year to $132.9 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $132.9 million (up 5940.91% YoY) and the FY2023 annual result came in at $134.0 million, up 5990.91% from the prior year.
• Notes Payables was little changed at $132.9 million in Q2 2024 per WST's latest filing, from $133.4 million in the prior quarter.
• Over the last five years, Notes Payables for WST reached as high as $134.0 million in Q4 2023 and fell as low as $2.2 million in Q4 2022.
• A 5-year average of $54.3 million and a median of $44.2 million in 2021 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2022 — Notes Payables sank 95.02% — and 2023, when it surged 5990.91%.
• Year by year, Notes Payables stood at $2.3 million in 2020, then surged by 1821.74% to $44.2 million in 2021, then plunged by 95.02% to $2.2 million in 2022, then jumped by 5990.91% to $134.0 million in 2023, then slipped by 0.82% to $132.9 million in 2024.
• According to Business Quant data, Notes Payables over the past three periods registered $132.9 million, $133.4 million, and $134.0 million for Q2 2024, Q1 2024, and Q4 2023 respectively.